Evidence map›Paper›PMID 38108073›Full record

ArticleOncology letters2024

Reduced expression of secretogranin VGF in laryngeal squamous cell carcinoma.

Francesca Gabanella, Daniela Maftei, Andrea Colizza, Emma Rullo, Mara Riminucci, Elena Pasqualucci, Maria Grazia Di Certo, Roberta Lattanzi, Roberta Possenti, Alessandro Corsi and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Francesca GabanellaCNR-Institute of Biochemistry and Cell Biology, Department of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Daniela MafteiDepartment of Physiology and Pharmacology V. Erspamer, Sapienza University of Rome, I-00185 Rome, Italy.
Andrea ColizzaDepartment of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Emma RulloDepartment of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy.
Mara RiminucciDepartment of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy.
Elena PasqualucciDepartment of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Maria Grazia Di CertoCNR-Institute of Biochemistry and Cell Biology, Department of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Roberta LattanziDepartment of Physiology and Pharmacology V. Erspamer, Sapienza University of Rome, I-00185 Rome, Italy.
Roberta PossentiDepartment of Systems Medicine, University of Rome Tor Vergata, I-00173 Rome, Italy.
Alessandro CorsiDepartment of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy.
Antonio GrecoDepartment of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Marco De VincentiisDepartment of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Cinzia SeveriniCNR-Institute of Biochemistry and Cell Biology, Department of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Massimo RalliDepartment of Sense Organs, Sapienza University of Rome, I-00161 Rome, Italy.
Sapienza University of Rome · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laryngeal cancer accounts for one-third of all head and neck tumors, with squamous cell carcinoma (SCC) being the most predominant type, followed by neuroendocrine tumors. Chromogranins, are commonly used as biomarkers for neuroendocrine tumors, including laryngeal cancer. It has been reported that secretogranin VGF, a member of the chromogranin family, can be also used as a significant biomarker for neuroendocrine tumors. However, the expression and role of VGF in laryngeal carcinomas have not been previously investigated. Therefore, the present study aimed to determine the expression levels of VGF in laryngeal SCC (LSCC). The present study collected tumor tissues, as well as serum samples, from a cohort of 15 patients with LSCC. The results of reverse transcription-quantitative PCR, western blot analysis and immunofluorescence assays showed that the selective VGF precursor was downregulated in patients with LSCC. Notably, in tumor tissue, the immunoreactivity for VGF was found in vimentin-positive cells, probably corresponding to T lymphocytes. The current preliminary study suggested that the reduced expression levels of VGF observed in tumor tissue and at the systemic level could sustain LSCC phenotype. Overall, VGF could be a potential biomarker for detecting neoplastic lesions with a higher risk of tumor invasiveness, even in non-neuroendocrine tumors.

Indexed as

chromograninshead and neck cancerlaryngeal squamous cell carcinomalarynx cancersecretograninssquamous cell carcinomasquamous cell carcinomasVGF

Identifiers

PMID38108073
PMCPMC10722547
OpenAlexW4389194548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.